Company Research Report: CellCarta

Company Overview

Name: CellCarta

Mission of the Company: CellCarta aims to advance precision medicine by providing comprehensive biomarker platforms and services to the biopharmaceutical industry, offering customized solutions for complex scientific testing needs.

Founded: The fusion of Caprion Biosciences and HistoGeneX in 2019 marked the establishment of CellCarta.

Key People in the Company:

Dusty Tenney, MSC - Chief Executive Officer

Anthony Mattacchione, MBA, CPA - Chief Financial Officer

Hayden Routledge, PhD - Chief Commercial Officer

Christopher Ung, MSc, MBA - Chief Scientific Business Officer

Louis Norton, PhD - Chief Information Officer

Kristien Verhoeven, MSc, PhD, MBA - Senior Vice President, Histopathology & Genomics Business Units

Todd Chermak, PhD - Senior Vice President, Immunology & Proteomics Business Units

Nancy El Sayegh - Vice President, General Counsel and Corporate Secretary

Ted Foss, PhD - Senior Vice President, Data Science and Management

Mark Kockx, MD, PhD - Chief Scientific Officer & Medical Director

Board of Directors:

David Spaight - Chairman of the Board

Martin Leblanc - Vice-Chairman, Co-founder of CellCarta Biosciences

Mark Kockx, PhD - Co-Founder and Board Member

Scientific Advisory Board:

James E Rothman, PhD - Chairman of Arsenal Capital Partners Healthcare Advisory Board

Scott Gottlieb, MD - Former Commissioner of the FDA

Others from prestigious institutions

Headquarters: No specific information on the headquarters location is available.

Number of Employees: No information is available.

Revenue: No information is available.

What is the Company Known For: CellCarta is recognized for its robust offerings in biomarker solutions and precision medicine, focusing on immune monitoring, histopathology, proteomics, and genomics.

Products

Testing Services and Solutions

Biomarker Solutions: Offer services like Discovery and Non-Clinical Services, and Clinical Biomarkers.

Immune Monitoring: Involves Basophil Activation Test (BAT), Cell Enumeration, Cellular Phenotyping, etc.

Proteomics and Genomics Services: Includes MS based Biomarker Services, Genomic Services like Digital PCR, Quantitative PCR, and RNA Sequencing.

Technologies

Flow Cytometry and Mass Cytometry (CyTOF): Used for advanced cell analysis.

Olink® PEA Technology: Quantification of protein biomarkers using minimal samples.

Spatial Biology and Single-Cell Sequencing: Cutting-edge technologies for detailed cellular analysis.

Therapeutic Expertise

Oncology, Cell Therapy, Infectious Diseases, Immunology, Neurosciences, Targeted Protein Degraders: Specialized services supporting various therapeutic domains.

Recent Developments

New Products and Services

CellEngine® Software: Provides cytometry analysis with advanced visualization features.

Jining, China Laboratory: Opened in 2019, offering services like flow cytometry, histopathology, genomics.

Partnerships and Expandments

Integration with Clinical Logistics Inc. (now CellCarta Logistics) and Biogazelle to expand logistics services.

Acquisitions that bolster specimen logistics and biomarker capabilities.

Research and Publications

November 23, 2023: Publication on integrated antibody and cellular immunity monitoring essential for next-generation vaccine development.

New Mobile Interfaces: Launch of CellCarta Chinese Mobile Website and WeChat Mini-Program announced on January 30, 2024.

Events

Participation in ASH 2024 in San Diego, CA from December 7, 2024, to December 10, 2024.

Additional Information

Recent conversations and scientific discussions featuring notable academics like Dr. Thomas Powles.

This report aims to encapsulate the critical components of CellCarta's operations, recent endeavors, and strategic movements within the precision medicine landscape, reflecting their expertise in delivering advanced scientific solutions globally.